Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats.
This article is from H. Wu and friends at the Jingling hospital within Nanjing University in China. it is published in the European Journal of cardio-throrac surgury.
Objective: Based on the findings that erythropoietin has been proved to be a multiple functional cytokine to attenuate ischemia-reperfusion (I/R) injury in various organs such as brain, heart, and kidney in animals, this experiment was designed to evaluate the effect of pretreatment with recombined human erythropoietin on I/R-induced lung injury. Methods: Left lungs of rats underwent 90min of ischemia and then were reperfused for up to 2h. Animals were randomly divided into three experimental groups as sham group, I/R group, and recombined human erythropoietin +I/R group (a single dose of recombined human erythropoietin was injected intraperitoneally 3000U/kg 24h prior to operation). Lung injury was evaluated according to semi-quantitive analysis of microscopic changes, tissue polymorphonuclear neutrophils (PMNs) accumulation (myeloperoxidase (MPO) activity), and pulmonary microvascular permeability (Evan’s blue dying method). Peripheral arterial and venous blood samples were obtained for blood-gas analysis after 5min occlusion of right lung hilus at the end of reperfusion. The serum concentration of tumor necrosis factor (TNF)-alpha was also measured by the method of enzyme-linked immunosorbent assay.
Results: Histological injury scoring revealed significantly lessened lung alveolus edema and neutrophils infiltration in the recombined human erythropoietin pretreated group compared with I/R group (p<0.05). The recombined human erythropoietin pretreated animals exhibited markedly decreased lung microvascular permeability (p<0.05) and myeloperoxidase activity (p<0.05). Blood-gas analysis demonstrated that the pretreated animals had significantly ameliorated pulmonary oxygenation function (p<0.05). The serum concentration of tumor necrosis factor-alpha in recombined human erythropoietin pretreated group was markedly decreased compared with that of I/R group (p<0.05).
Conclusions: Pretreatment with recombined human erythropoietin appears to attenuate I/R-induced lung injury. This function is partly related with the capacity that recombined human erythropoietin inhibits the accumulation of polymorphonuclear neutrophils in lung tissue and decreases the systematic expression of tumor necrosis factor-alpha.
The pubmed ID is 16675226